Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 1 Of 2)

This article was originally published in PharmAsia News

Executive Summary

Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.

You may also be interested in...



In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

Calibrating a medicine price to a lower level to suit local needs is not a new concept for GlaxoSmithKline, which uses a tiered pricing structure, generally calculated based on parameters like GDP, per capita income of a specific country, medical access quotients and health insurance programs.

In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

Calibrating a medicine price to a lower level to suit local needs is not a new concept for GlaxoSmithKline, which uses a tiered pricing structure, generally calculated based on parameters like GDP, per capita income of a specific country, medical access quotients and health insurance programs.

In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket

Related Content

Latest News
UsernamePublicRestriction

Register

SC073616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel